Monoclonal Anti-Human IgG2 antibody produced in mouse

clone HP-6014, ascites fluid

Monoclonal Anti-Human IgG2
Pricing and availability is not currently available.

Quality Level

biological source


antibody form

ascites fluid

antibody product type

secondary antibodies


HP-6014, monoclonal


15 mM sodium azide


indirect ELISA: 1:5,000





shipped in

dry ice

storage temp.


Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Monoclonal Anti-Human IgG2 (mouse IgG1 isotype) is derived from the hybridoma produced by the fusion of mouse myeloma cells and splenocytes from an immunized mouse. Human IgG consists of four subclasses.


The antibody is specific for human IgG2 and is non-reactive with other IgG subclasses. This clone has been singled out as the most widely applicable IgG2 specific monoclonal antibody by the IUIS/WHO study.


Monoclonal Anti-Human IgG2 antibody has been used in in enzyme linked immunosorbent assay (ELISA) and in western blotting.
It may also be used:
  • in imprint immunofixation
  • in immunofluorometric assay
  • in hemagglutination
  • in hemagglutination inhibition
  • in particle counting immunoassay
  • in detection of cytoplasmic IgG

Biochem/physiol Actions

Anti-polysaccharide responses are mainly of the IgG2 sub-class while protein antigens give rise to IgG1 and IgG3 antibodies. Lipopolysaccharides stimulate an IgG2 response in peripheral blood leukocytes (PBL′s).


Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.


NONH for all modes of transport

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Identification of immune biomarkers related to disease progression and treatment efficacy in human visceral leishmaniasis
Portela A S B, et al.
Immunobiology, 223(3), 303-309 (2018)
A conserved Leishmania hypothetical protein evaluated for the serodiagnosis of canine and human visceral and tegumentary leishmaniasis, as well as a serological marker for the posttreatment patient follow-up
Ribeiro P A, et al.
Diagnostic Microbiology and Infectious Disease, 92(3), 196-203 (2018)
Negative immunodiffusion test results obtained with sera of paracoccidioidomycosis patients may be related to low-avidity immunoglobulin G2 antibodies directed against carbohydrate epitopes
Neves AR, et al.
Clinical and Diagnostic Laboratory Immunology, 10(5), 802-807 (2003)
Z Lazarova et al.
The Journal of investigative dermatology, 114(1), 178-184 (2000-01-05)
Patients with one form of cicatricial pemphigoid have IgG antibasement membrane autoantibodies against laminin 5 (alpha3beta3gamma2). Although passive transfer of rabbit anti-laminin 5 IgG to neonatal mice has been shown to induce subepidermal blisters that mimic those in patients, it...
Anna Babakhanyan et al.
Malaria journal, 14, 480-480 (2015-12-03)
Antibodies (Ab) to VAR2CSA prevent Plasmodium falciparum-infected erythrocytes from sequestrating in the placenta, i.e., prevent placental malaria (PM). The specificity of Ab to VAR2CSA associated with absence of PM is unknown. Accordingly, differences in the specificity of Ab to VAR2CSA...
Antibody-based serology tests are useful in identifying subjects with an adaptive immune response to the SARS-CoV-2 virus. Anti-human immunoglobulin antibodies allow for quick and simple, yet reliable assays with easy readouts and can also be adapted for high-throughput screening.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.